March 26 (Reuters) - MEI Pharma Inc :
* MEI PHARMA REPORTS UPDATE FROM CLINICAL STUDY EVALUATING ORAL CDK9 INHIBITOR VORUCICLIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
* MEI PHARMA INC - ENROLLMENT INITIATED IN 12-PATIENT EXPANSION COHORT EVALUATING VORUCICLIB PLUS VENETOCLAX IN ONGOING PHASE 1 STUDY
* MEI PHARMA INC - ANTI-LEUKEMIC ACTIVITY ACROSS MULTIPLE HEAVILY PRETREATED PATIENTS DEMONSTRATED ALONG WITH ANTICIPATED DECREASES IN MCL-1
* MEI PHARMA INC - NO EVIDENCE OF OVERLAPPING TOXICITY, AND NO DOSE LIMITING TOXICITIES OBSERVED TO DATE IN DOSE ESCALATION COHORTS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Comments